Pathophysiological basis of liver disease in cystic fibrosis employing a DeltaF508 mouse model
about
New pathophysiological concepts underlying pathogenesis of pigment gallstonesAetiopathogenesis of liver changes in the course of cystic fibrosis, considering disturbances of the bile acid profile as well as genetic and immunological factorsGallstones in patients with liver cirrhosis: incidence, etiology, clinical and therapeutical aspects.Pathophysiological preconditions promoting mixed "black" pigment plus cholesterol gallstones in a DeltaF508 mouse model of cystic fibrosis.Impaired cholecystokinin-induced gallbladder emptying incriminated in spontaneous "black" pigment gallstone formation in germfree Swiss Webster mice.Animal models of gastrointestinal and liver diseases. Animal models of cystic fibrosis: gastrointestinal, pancreatic, and hepatobiliary disease and pathophysiology.Genetic Inhibition Of The Ubiquitin Ligase Rnf5 Attenuates Phenotypes Associated To F508del Cystic Fibrosis Mutation.CFTR dysfunction predisposes to fibrotic liver disease in a murine modelImpact of cystic fibrosis disease on archaea and bacteria composition of gut microbiota.Comparative biology of cystic fibrosis animal modelsThe cystic fibrosis intestine.Regulation of hepatic sulfotransferase (SULT) 1E1 expression and effects on estrogenic activity in cystic fibrosis (CF).Transporters in cholelithiasis.Cystic fibrosis: an update for clinicians. Part 2: hepatobiliary and pancreatic manifestations.Defects in gallbladder emptying and bile Acid homeostasis in mice with cystic fibrosis transmembrane conductance regulator deficiencies.Ursodeoxycholate modulates bile flow and bile salt pool independently from the cystic fibrosis transmembrane regulator (Cftr) in mice.
P2860
Q26826934-1867E479-B0D1-42B4-B73B-5289C1A120BDQ26999270-1598D956-F339-4399-B918-F7BC45D64D1DQ33780136-9BC7133F-116C-46EF-9EDE-C8F5119EB292Q33994808-BC7910AA-AC6C-4646-903B-41210ADC7E9EQ35086405-E95135B7-EC19-4A2C-897E-ED92657F1E36Q35178642-22D989D6-83B9-49C2-B41A-A2C75451AD60Q35693982-8302FCD4-E2F8-4288-AB08-DDAE78FA06E5Q36176038-9DD99F09-981D-4023-90C3-5EEC71BAD0F9Q36181782-A4F09A02-B0E7-4617-9469-9564A4BE0023Q36744020-CB1B2646-B204-4F7C-9383-04269A3B82F4Q37122355-0E74A8FA-42D1-4215-82AA-0D456DC0D8E9Q37373924-5E826858-8525-4EE1-9059-C59AE46EE69EQ38013076-7B728F66-8502-450A-ABFC-B6C0ED04EEB6Q38252636-7065EA38-DD68-457E-9B1C-11906F3CBA8CQ43008641-3353DA28-649C-48D6-B102-A30B780A4E4EQ48190174-7549AD35-85AE-4F89-8C91-FA83CAD2CBFC
P2860
Pathophysiological basis of liver disease in cystic fibrosis employing a DeltaF508 mouse model
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 24 April 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Pathophysiological basis of li ...... loying a DeltaF508 mouse model
@en
Pathophysiological basis of li ...... oying a DeltaF508 mouse model.
@nl
type
label
Pathophysiological basis of li ...... loying a DeltaF508 mouse model
@en
Pathophysiological basis of li ...... oying a DeltaF508 mouse model.
@nl
prefLabel
Pathophysiological basis of li ...... loying a DeltaF508 mouse model
@en
Pathophysiological basis of li ...... oying a DeltaF508 mouse model.
@nl
P2093
P2860
P356
P1476
Pathophysiological basis of li ...... loying a DeltaF508 mouse model
@en
P2093
Annemarie L Broderick
Folke Freudenberg
Jonathan N Glickman
Martin C Carey
Monika R Leonard
P2860
P304
P356
10.1152/AJPGI.00181.2007
P577
2008-04-24T00:00:00Z